Thorsten Rosenbaum

1.5k total citations
39 papers, 899 citations indexed

About

Thorsten Rosenbaum is a scholar working on Neurology, Rheumatology and Molecular Biology. According to data from OpenAlex, Thorsten Rosenbaum has authored 39 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Neurology, 12 papers in Rheumatology and 11 papers in Molecular Biology. Recurrent topics in Thorsten Rosenbaum's work include Neurofibromatosis and Schwannoma Cases (24 papers), Sarcoma Diagnosis and Treatment (11 papers) and Soft tissue tumor case studies (10 papers). Thorsten Rosenbaum is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (24 papers), Sarcoma Diagnosis and Treatment (11 papers) and Soft tissue tumor case studies (10 papers). Thorsten Rosenbaum collaborates with scholars based in Germany, United States and Austria. Thorsten Rosenbaum's co-authors include Nancy Ratner, Ertan Mayatepek, Radhika P. Atit, Larry S. Sherman, Adrienne D. Cox, Jörg Schaper, Felix Distelmaier, H. G. Lenard, Conxi Lázaro and Ying L. Boissy and has published in prestigious journals such as Journal of Biological Chemistry, Nature Genetics and Development.

In The Last Decade

Thorsten Rosenbaum

36 papers receiving 879 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thorsten Rosenbaum Germany 19 582 237 190 167 158 39 899
David Kronn United States 15 284 0.5× 362 1.5× 79 0.4× 274 1.6× 195 1.2× 35 1.0k
Takafumi Ide Japan 14 256 0.4× 281 1.2× 146 0.8× 48 0.3× 179 1.1× 33 797
A. Bornemann Germany 17 286 0.5× 239 1.0× 100 0.5× 86 0.5× 145 0.9× 42 755
Stefan Probst‐Cousin Germany 16 309 0.5× 169 0.7× 118 0.6× 51 0.3× 141 0.9× 34 745
Guilhem Solé France 15 176 0.3× 250 1.1× 95 0.5× 107 0.6× 64 0.4× 62 731
Ken Morii Japan 17 147 0.3× 233 1.0× 145 0.8× 73 0.4× 56 0.4× 54 742
Argirios Dinopoulos Greece 14 153 0.3× 410 1.7× 65 0.3× 40 0.2× 65 0.4× 43 998
Marja Hietala Finland 17 159 0.3× 485 2.0× 150 0.8× 46 0.3× 52 0.3× 37 918
Naoko Sanno Japan 25 195 0.3× 382 1.6× 70 0.4× 58 0.3× 371 2.3× 77 1.6k
Lilyana Angelov United States 7 219 0.4× 195 0.8× 73 0.4× 43 0.3× 50 0.3× 11 748

Countries citing papers authored by Thorsten Rosenbaum

Since Specialization
Citations

This map shows the geographic impact of Thorsten Rosenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorsten Rosenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorsten Rosenbaum more than expected).

Fields of papers citing papers by Thorsten Rosenbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorsten Rosenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorsten Rosenbaum. The network helps show where Thorsten Rosenbaum may publish in the future.

Co-authorship network of co-authors of Thorsten Rosenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Thorsten Rosenbaum. A scholar is included among the top collaborators of Thorsten Rosenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thorsten Rosenbaum. Thorsten Rosenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Azizi, Amedeo A., Darren Hargrave, P. Wolkenstein, et al.. (2024). Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-Oncology Practice. 11(5). 515–531. 5 indexed citations
2.
3.
Friedrich, Reinhard E., Jozef Zustin, Andreas M. Luebke, et al.. (2021). Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey. In Vivo. 35(3). 1711–1736. 4 indexed citations
4.
Rosenbaum, Thorsten, et al.. (2021). Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option. Neuropediatrics. 53(1). 52–60. 10 indexed citations
5.
Kehrer‐Sawatzki, Hildegard, Lan Kluwe, Johannes Salamon, et al.. (2020). Clinical characterization of children and adolescents with NF1 microdeletions. Child s Nervous System. 36(10). 2297–2310. 19 indexed citations
6.
Röhrig, Andreas, et al.. (2019). Trametinib Induces Neurofibroma Shrinkage and Enables Surgery. Neuropediatrics. 50(5). 300–303. 29 indexed citations
7.
Czeschik, Johanna Christina, Ute Hehr, Britta Hartmann, et al.. (2013). 160 kb deletion in ISPD unmasking a recessive mutation in a patient with Walker–Warburg syndrome. European Journal of Medical Genetics. 56(12). 689–694. 18 indexed citations
8.
Mayatepek, Ertan, et al.. (2008). Schwann Cells From Human Neurofibromas Show Increased Proliferation Rates Under the Influence of Progesterone. Pediatric Research. 64(1). 40–43. 21 indexed citations
9.
Distelmaier, Felix, et al.. (2007). “How Much Brain Is Really Necessary?” A Case of Complex Cerebral Malformation and Its Clinical Course. Journal of Child Neurology. 22(6). 756–760. 3 indexed citations
10.
Maertens, Ophélia, Hilde Brems, Jo Vandesompele, et al.. (2006). ComprehensiveNF1 screening on cultured Schwann cells from neurofibromas. Human Mutation. 27(10). 1030–1040. 82 indexed citations
11.
Distelmaier, Felix, Raimund Fahsold, Guido Reifenberger, et al.. (2006). Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Child s Nervous System. 23(3). 343–347. 11 indexed citations
12.
Distelmaier, Felix, et al.. (2006). Secondary pseudotumor cerebri in pediatric oncology and hematology: An unpredictable condition of varying etiology. Pediatric Blood & Cancer. 49(7). 1029–1033. 5 indexed citations
13.
Schaper, Jörg, et al.. (2005). Subdural hematoma as clinical presentation of osteogenesis imperfecta. Pediatric Neurology. 32(2). 140–142. 18 indexed citations
14.
Distelmaier, Felix, et al.. (2005). Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain and Development. 28(3). 190–195. 52 indexed citations
15.
Schaper, Jörg, et al.. (2004). Fanconi Syndrome Caused by Antiepileptic Therapy with Valproic Acid. Epilepsia. 45(7). 868–871. 42 indexed citations
16.
Holtkamp, Nikola, David Reuß, Isis Atallah, et al.. (2004). Subclassification of Nerve Sheath Tumors by Gene Expression Profiling. Brain Pathology. 14(3). 258–264. 32 indexed citations
17.
Sherman, Larry S., Radhika P. Atit, Thorsten Rosenbaum, Adrienne D. Cox, & Nancy Ratner. (2000). Single Cell Ras-GTP Analysis Reveals Altered Ras Activity in a Subpopulation of Neurofibroma Schwann Cells but Not Fibroblasts. Journal of Biological Chemistry. 275(39). 30740–30745. 112 indexed citations
18.
Rosenbaum, Thorsten, et al.. (2000). Long-term culture and characterization of human neurofibroma-derived Schwann cells. Journal of Neuroscience Research. 61(5). 524–532. 36 indexed citations
19.
Rosenbaum, Thorsten, Haesun A. Kim, Ying L. Boissy, Bo Ling, & Nancy Ratner. (1999). Neurofibromin, the Neurofibromatosis Type 1 Ras‐GAP, Is Required for Appropriate P0 Expression and Myelination. Annals of the New York Academy of Sciences. 883(1). 203–214. 21 indexed citations
20.
Guénard, Véronique, et al.. (1995). Effect of transforming growth factor‐β1 and ‐β2 on Schwann cell proliferation on neurites. Glia. 13(4). 309–318. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Kronn Breakdown of academic impact, for papers by Takafumi Ide Breakdown of academic impact, for papers by A. Bornemann Breakdown of academic impact, for papers by Stefan Probst‐Cousin Breakdown of academic impact, for papers by Guilhem Solé Breakdown of academic impact, for papers by Ken Morii Breakdown of academic impact, for papers by Argirios Dinopoulos Breakdown of academic impact, for papers by Marja Hietala Breakdown of academic impact, for papers by Naoko Sanno Breakdown of academic impact, for papers by Lilyana Angelov
Rankless by CCL
2026